Second Clinical Site Opened in Ph 1 Clinical Study of JBZ-001
“We are excited to add a second center to our first-in-human trial, serving the Mountain Region and allowing more geographical access to patients,” said Tamara Jovonovich, PhD, Chief Executive Officer of Jabez Biosciences. “We are currently enrolling our second dose cohort in the dose-escalation portion of the study. Opening the trial at a second site expands our reach and our hope of delivering best-in-class therapies that address the unmet needs of cancer patients. JBZ-001’s unique mechanism of action, which targets multiple pathways beyond nucleotide depletion, offers hope for a broad spectrum of oncological indications, and we are eager to see its potential unfold in this trial.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).